Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload
source: British Journal of Haematology
year: 2015
authors: Aygun B, Mortier NA, Kesler K, Lockhart A, Schultz WH, Cohen AR, Alvarez O, Rogers ZR, Kwiatkowski JL, Miller ST, Sylvestre P, Iyer R, Lane PA, Ware RE
summary/abstract:Serial phlebotomy was performed on sixty children with sickle cell anaemia, stroke and transfusional iron overload randomized to hydroxycarbamide in the Stroke With Transfusions Changing to Hydroxyurea trial. There were 927 phlebotomy procedures with only 33 adverse events, all of which were grade 2. Among 23 children completing 30 months of study treatment, the net iron balance was favourable (-8·7 mg Fe/kg) with significant decrease in ferritin, although liver iron concentration remained unchanged. Therapeutic phlebotomy was safe and well-tolerated, with net iron removal in most children who completed 30 months of protocol-directed treatment.
organization: Steven and Alexandra Cohen Children's Medical Center, New Hyde Park, NYDOI: 10.1111/bjh.13280
read more full text
Related Content
-
2017 April 29 SiNERGe Webinar on Bone Marrow Transplantshttps://www.youtube.com/watch?v=HudIvtS_...
-
LentiGlobin Shows Positive Effects in Severe Sickle Cell Disease Patients, Phase 1/2 Data ReportsBluebird bio presented new positive resu...
-
Incidence and Risk of Delayed Hemolytic Transfusion Reaction in Sickle Cell Disease Patients Based on a Prospective ...Background: Delayed hemolytic transfusi...
-
Living With Sickle Cell Disease: One Person’s Story of Pain and Prejudice and Their Hopes for a Stem Cell TherapyMy name is Marissa Cors, I have sickle c...
-
APS Scientific Meeting 2019The American Pain Society will hold its ...
-
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell DiseaseBACKGROUND: The up-regulation of P-selec...
-
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy PlatformGlobal biotherapeutics leader CSL Behrin...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
+myBinder